Search

Begin New Search Topic Vaccine Political Geography United States of America

1. Boosting Childhood Vaccination Rates Post-Pandemic: Lessons from Five Countries

Author:
Irene Papanicolas, Robert A. Berenson, and Laura Skopec
Publication Date:
10-2024
Content Type:
Policy Brief
Institution:
Commonwealth Fund
Abstract:
Issue: Childhood vaccination rates fell worldwide during the COVID-19 pandemic. However, reductions in childhood vaccination were not universal, which may be related to differences in vaccine eligibility, vaccine hesitancy, and vaccine administration programs across countries. Goals: Explore how childhood vaccination rates changed during the COVID-19 pandemic in five high-income countries with varying approaches to vaccine policy. Methods: Surveys of in-country experts and analysis of secondary data sources in Australia, Germany, Singapore, the United Kingdom, and the United States. Key Findings and Conclusion: While vaccination rates fell worldwide during the COVID-19 pandemic, the high-income countries in our study maintained high childhood vaccination rates for polio and measles-mumps-rubella (MMR) near or above the herd immunity threshold (80% for polio and 95% for measles). Australia and Singapore, which have the strictest vaccine requirements, boasted the highest polio vaccination rates in both 2018 and 2021. No countries require the human papillomavirus (HPV) vaccination nationwide, but Australia, Singapore, and the U.K. have school-based HPV vaccination programs and high vaccination rates. Strong vaccine requirements, combined with school-based immunization or catch-up programs, may help boost childhood vaccination rates where they lagged during the pandemic.
Topic:
Children, Vaccine, COVID-19, and Healthcare System
Political Geography:
United Kingdom, Germany, Australia, Singapore, and United States of America

2. COVID-19 vaccine supply chains and the Defense Production Act

Author:
Chad P. Bown
Publication Date:
06-2022
Content Type:
Working Paper
Institution:
Peterson Institute for International Economics (PIIE)
Abstract:
In response to the COVID-19 pandemic, the US government used novel policies to accelerate research, development, and production of a diversified portfolio of new vaccines. This paper begins by describing the Defense Production Act (DPA) of 1950 and the initial “priority-rated” contracts agreed to under Operation Warp Speed in 2020 to expedite manufacturing and achieve scale, which succeeded in producing hundreds of millions of doses of COVID-19 vaccines by early 2021. However, a puzzle soon emerged, as the scale of US vaccine production was shortly thereafter overtaken by plants in the European Union and India. The paper investigates the tradeoffs US policymakers faced in early 2021 once much of the initial uncertainty about the safety and effectiveness of many COVID-19 vaccines had been resolved—about whether to recalibrate contracts to expand production capacity to help meet global, instead of US, vaccine demand. It also examines the emergence of input shortages and assesses whether both the price constraints implicit in the 2020 DPA contracts and business decisions made to quicken the process of bringing new vaccine plants online globally inadvertently exacerbated them. It also explores the potential need for complementary, input capacity enhancing policies in the face of highly fragmented, cross-border COVID-19 vaccine supply chains.
Topic:
Crisis Management, Vaccine, COVID-19, and Supply Chains
Political Geography:
North America and United States of America

3. US-China vaccine diplomacy: Lessons from Latin America and the Caribbean

Author:
María Eugenia Brizuela de Ávila, Bosco Marti, Riyad Insanally, and Claudia Trevisan
Publication Date:
02-2022
Content Type:
Special Report
Institution:
Atlantic Council
Abstract:
COVID-19 has laid bare the competing strategies and practices of the United States and China to amass further clout in Latin America and the Caribbean (LAC). In many ways, the pandemic is quickly accelerating a regional trend seen over the last decade: China uses its growing economic and diplomatic muscle to provide an alternative to US activities and interests. The implications of diverging COVID-19 responses, notably at the onset of the pandemic’s rise in the region, will reverberate beyond the health sector. What might the differing US and China pandemic approaches portend for future influence in the region? For the United States and China, the pandemic has opened new opportunities to deepen regional ties. Both countries’ assistance eventually centered on vaccine diplomacy, but China was first out of the gates in offering vaccinations beyond its borders. For LAC, its interactions with the United States and China during the pandemic are emblematic of broader trends: China provides an alternative to LAC during crisis moments; and regional leaders use US-Chinese competition to their advantage. Both instances are visible in the region, including in the four geographic areas analyzed in the following pages: Central America, Trinidad and Tobago (T&T), Brazil, and Mexico. In each case, distinct US and Chinese engagement at various stages of the pandemic—along with the host countries’ own actions and reactions—have yielded short-term results and some that are likely to persist. In Central America, China provided strategic diplomatic messaging alongside vaccine shipments, but the United States donated more vaccines. In T&T, Chinese vaccines were accompanied by a new loan, and the country’s prime minister applied a pragmatic approach to acquire vaccines from both the United States and China. For Brazil, laboratory-to-laboratory agreements highlighted a different version of vaccine diplomacy: one that occurs at the subnational level. In Mexico, numerous diplomatic exchanges occurred alongside substantial vaccine purchases from US and Chinese manufacturers. Vaccine-related diplomacy also contributes to an evolving discussion about the different ways China and the United States more broadly engage the region—and vice versa. Starting from a low base, Chinese engagement with LAC has focused on and grown significantly in diplomacy, trade, and investment over the last decade. China is either the first- or second-largest trading partner for many countries in the Americas and a top source of foreign direct investment among its allies. Current US strategy in the region similarly reflects a new sense of deploying diplomatic tools to advance hemispheric prosperity, while doing so as part of a broader vision that reflects partnering to address global challenges—from climate change and the instability that sparks migration to shoring up democracy and addressing corruption. Overall, the region’s proximity, shared peoples, history, and borders with the United States provide greater depth and multidimensionality to the relationship. Consequently, vaccine diplomacy represents a greater marginal opportunity for China to broaden and deepen regional ties.
Topic:
Diplomacy, Bilateral Relations, Vaccine, and COVID-19
Political Geography:
China, Latin America, Caribbean, and United States of America

4. Quad Economy and Technology Task Force Report

Author:
Gateway House
Publication Date:
08-2021
Content Type:
Special Report
Institution:
Gateway House: Indian Council on Global Relations
Abstract:
Conceived in 2020, the task force studied promising areas for cooperation between the Quad countries beyond their pre-existing maritime security partnership. The report highlights the need to increase economic and technological interdependence among the Quad countries and to establish common and updated rules and standards for emerging technologies in five study areas. The unique mix of the group – three developed and one developing nation, three Pacific and one Indian Ocean nation, three producer-trading nations with one massive emerging market – lends itself to innovation, experimentation and cooperation that can be a template for a new, post-pandemic geopolitical era.
Topic:
Climate Change, International Cooperation, Science and Technology, Economy, Vaccine, and COVID-19
Political Geography:
Japan, India, Australia, and United States of America

5. Will the Biden Administration Support Global US Leadership in the Innovative Medicines Industry?

Author:
Thomas J. Duesterberg
Publication Date:
01-2021
Content Type:
Policy Brief
Institution:
Hudson Institute
Abstract:
Given the historically unprecedented speed with which the US pharmaceutical industry has developed COVID-19 vaccines—3 of the 4 first products likely to be approved for marketing are almost certainly from US firms—it would seem appropriate for a renewed sense of confidence, support and even acclaim for the economic model that lies behind this success. Instead, the sector remains under pressure to lower prices and protections for its patented products, both in the United States and globally. It is worth noting that the entire world benefits from the new medical advances in treating the worst pandemic in at least 50 years. Instead, President Trump has continued to criticize the industry for its pricing model for newly developed drugs, while countries such as India, Pakistan, and Brazil call for breaching of the patent shield for the new vaccines (and recent treatments such as those for HIV and Hepatitis C), and developed countries in Europe, East Asia, as well as Canada, persist in questioning the medical value of the new medicines to their citizens.1 To add to the current uncertainty about US leadership, there is ever-increasing competition from China in terms of basic science and pharmaceutical products. The Chinese national goal of self-sufficiency in these two fields has resulted in a huge increase in research and development funding and purchases of leading biotechnology firms in the United States and Europe. At the same time, China’s global market share in generic drugs and active pharmaceutical ingredients (APIs) is steadily growing. Chinese government funding for research in these fields has grown by 20 percent annually since 2008. The incoming Biden administration is calling for new pricing models and the use of compulsory licensing for some new products, especially those related to the new virus pandemics. Compulsory licensing allows a government to license entities other than the patent holder to produce and sell patented products without the patent holder’s permission. If the economic and scientific model which promotes constant advances in medicines and new treatments is to survive, the current domestic ecosystem for research and development ought to be strengthened, instead of being undermined by reducing private sector incentives and weakening the protection of intellectual property (IP). Additionally, ways to address the problem with other countries enjoying a “free ride” at the expense of US consumers and public health systems, need to be considered.
Topic:
Health Care Policy, Manufacturing, Innovation, Vaccine, COVID-19, Medicine, and Pharmaceuticals
Political Geography:
North America and United States of America

6. How COVID-19 vaccine supply chains emerged in the midst of a pandemic

Author:
Chad P. Bown
Publication Date:
08-2021
Content Type:
Working Paper
Institution:
Peterson Institute for International Economics (PIIE)
Abstract:
Many months after COVID-19 vaccines were first authorized for public use, still limited supplies could only partially reduce the devastating loss of life and economic costs caused by the pandemic. Could additional vaccine doses have been manufactured more quickly some other way? Would alternative policy choices have made a difference? This paper provides a simple analytical framework through which to view the contours of the vaccine value chain. It then creates a new database that maps the COVID-19 vaccines of Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, Novavax, and CureVac to the product- and location-specific manufacturing supply chains that emerged in 2020 and 2021. It describes the choppy process through which dozens of other companies at nearly 100 geographically distributed facilities came together to scale up global manufacturing. The paper catalogues major pandemic policy initiatives—such as the United States' Operation Warp Speed—that are likely to have affected the timing and formation of those vaccine supply chains. Given the data, a final section identifies further questions for researchers and policymakers.
Topic:
Vaccine, COVID-19, Health Crisis, and Supply Chains
Political Geography:
Global Focus and United States of America

7. Vaccine Diplomacy: A Tool in the Rivalry for Influence in Latin America

Author:
Bartlomiej Znojek
Publication Date:
09-2021
Content Type:
Special Report
Institution:
The Polish Institute of International Affairs
Abstract:
The uneven access to COVID-19 vaccines in Latin American countries has resulted in a widely varied pace of immunisation. The region has relied mainly on direct purchases from China and Russia, among others, the global COVAX initiative, and donations from the U.S. and other countries. Russia, China, and the U.S. in particular are using this “vaccine diplomacy” to boost their own political and economic influence in Latin America. The EU has been trying to position itself against that rivalry, for example, through significant funding for vaccine access and distribution initiatives. These efforts require, however, more efficient promotion of the Union’s engagement.
Topic:
Diplomacy, Vaccine, COVID-19, and Rivalry
Political Geography:
Russia, China, Latin America, and United States of America

8. China’s Vaccine Diplomacy Amid COVID – 19 Pandemic: A Case Study of South Asia

Author:
Shabana Fayyaz and Tabinda Siddiqui
Publication Date:
07-2021
Content Type:
Journal Article
Journal:
South Asian Studies
Institution:
Department of Political Science, University of the Punjab
Abstract:
COVID-19 onset has questioned the proclaimed notions of Globalization such as shared prosperity and security across the board. The ongoing pandemic once again calls for collective action in men and material terms rather than erecting technology barriers and doubting the intentions of each other. This paper aims to address the following inter-related queries: What is the nature of China‟s health-based assistance to the South Asian states for mitigating the COVID-19 risks? How and why do the United States and India remain skeptical of Chinese anti COVID- 19 Vaccine efforts? And how do other South Asian states perceive Chinese contributions to deal with the ongoing Pandemic? And, finally what lessons can be learned from this divergent debate centered on: Chinese Vaccine Diplomacy? Comparison and contrast of the available information is employed as an analytical technique to determine the nature of skepticism surrounding the Chinese vaccination campaign in South Asia. Consulting data on three various accounts assisted to conclude the findings of this research paper. The findings of this study establish that Western and Indian skepticism, directed against Chinese health diplomacy in South Asia is motivated by their geopolitical contestations with China. In nutshell, the paper‟s main thrust is to stress the essential value of mutual cooperation in dealing with the Pandemic like COVID-19. There is a need to embrace the concept of „holistic security‟ in the highly interconnected world of today and tomorrow.
Topic:
Diplomacy, Globalization, Crisis Management, Vaccine, and COVID-19
Political Geography:
Pakistan, China, South Asia, and United States of America

9. Vaccinating America

Author:
Committee for Economic Development of the Conference Board
Publication Date:
04-2021
Content Type:
Policy Brief
Institution:
The Conference Board
Abstract:
In December 2020, one year after the COVID-19 virus had been reported in China, the Food and Drug Administration (FDA) granted emergency use authorization in back-to-back announcements for the Pfizer/BioNTech and Moderna/NIAID vaccines. This was by far the fastest vaccine development in history. A typical vaccine took 10 years to develop, with the most rapid previous development being the four years it had taken for the mumps vaccine in 1967.1 And these two vaccines were of a new type, utilizing messenger RNA (mRNA). While mRNA had been studied for years, the unique spike protein of the coronavirus that causes COVID-19 provided a first opportunity to respond with an mRNA vaccine.2 The ensuing technological and scientific success could not have been accomplished without the collaboration of the private and public sectors. The distribution of the vaccine nationally could not have been accomplished without the major delivery companies stepping up to meet the challenges of on-time distribution of the vaccines, which required very cold storage. The research, development, and nationwide distribution of the vaccines has evoked comparisons to the private-public sector collaboration during WWII that led to the Manhattan Project’s rapid and dramatic scientific breakthroughs.3 After death tolls climbed into the hundreds of thousands, the vaccine announcements provided hope that there may be light at the end of the very dark COVID-19 tunnel. By the end of May, the United States is expected to have sufficient vaccine supply for the entire adult American population. But the challenge to manufacture, distribute, and administer the vaccinations quickly, efficiently, and fairly, in a race against continued infection and the emergence of variants of the virus here and all around the world, requires continued collaboration between the public and private sectors. The US and the world must win that race between vaccination and mutation to achieve “herd immunity” and return to normality in daily life and the economy. The stakes are high for both the current crisis and the inevitable pandemics of the future. For this reason, the following analysis offers a diagnosis of the current episode, and recommendations for today and tomorrow.
Topic:
Public Health, Vaccine, and COVID-19
Political Geography:
North America and United States of America

10. Religious Identities and the Race Against the Virus: Engaging Faith Communities on COVID-19 Vaccination

Author:
PRRI Staff
Publication Date:
04-2021
Content Type:
Special Report
Institution:
PRRI: Public Religion Research Institute
Abstract:
As the U.S. navigates evolving dynamics related to COVID-19 vaccine hesitancy and access, there has been a dearth of hard data to understand the cultural dynamics of this problem, and even less rigorous data available to understand how faith-based interventions might mitigate vaccine hesitancy and resistance. The PRRI–IFYC Religion and the Vaccine Survey, the largest study conducted to date in this area, reveals that faith-based approaches supporting vaccine uptake can influence members of key hesitant groups to get vaccinated and thus can be a vital tool for the public health community as we work toward herd immunity. Faith-based approaches are influential among vaccine hesitant communities. More than one in four (26%) Americans who are hesitant to get a COVID-19 vaccine, and even 8% of those who are resistant to getting a vaccine, report that at least one of six faith-based approaches supporting vaccinations would make them more likely to get vaccinated.
Topic:
Religion, Public Health, Vaccine, Pandemic, and COVID-19
Political Geography:
North America and United States of America